| Protocol Number |
Title |
2003NT036
|
ALTE03N1 Key Adverse Events After Childhood Cancer (COG study) |
2003NT049
|
ABTR01B1 A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors |
2003NT064
|
Metabolic Syndrome in Childhood Cancer Survivors |
2006CG033
|
COG ADVL0413: A Phase I Study of the RAF Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children with Refractory Solid Tumors or Refractory Leukemias |
2006LS032
|
MT2005-21: Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors |
2006NT012
|
MT2006-27: Bone Mineral Resorption In Children After Hematopoetic Stem Cell Transplantation |
2007CG010
|
COG ADVL0612: A Phase I Study of Sunitinib, an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Children with Refractory Solid Tumors |
2007CG076
|
ASCT0521: Phase II Open Label Study Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplant. |
2007IS095
|
Protherics PR001-CLN-pro016: An Open Label Treatment Protocol for the Use of Voraxase as Adjunctive Treatment for Patients Experiencing or Are At Risk of Methotrexate Toxicity. |
2007LS022
|
MT2006-01: Phase I Study of Infusion of Umbilical Cord Blood (UCB) Derived CD25+ CD4+ T-Regulatory (Treg) Cells After Non-Myeloablative Cord Blood Transplantation |
2007LS072
|
MT2007-07: Conditioning for Graft Failure after Hematopoietic Stem Cell Transplantation |
2007NT059
|
ABTR06C1: Pharmakokinetics of Daunomycin in Children |
2007NT121
|
A Phase I Open-Label Study of the Safety and Pharmacokinetics of Repeated-Dose Micafungin (FK463) in Children (2-5yrs and 6-11 yrs) and Adolescents (12-16 yrs.) with Esophageal Candidiasis or other Invasive Candidiasis (Astellas 9463-CL-2101) |
2007NT123
|
2007-18R: Chronic GVHD Cohort Protocol |
2007UC002
|
MT2006-07 Reduced Intensity Hematopoietic Cell Transplantation for Patients with Resistant Langerhans Cell Histiocytosis |
2008CG030
|
ANBL0531 Response-and Biology-based Therapy for Intermediate-risk Neuroblastoma |
2008CG164
|
COG ADVL0812 A Phase I Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children with Relapsed/Refractory Solid Tumors and Leukemia |
2008NTCG101
|
COG ANBL00B1 "Neuroblastoma Biology Studies" |
2008NTCG128
|
COG ADVL06B1 A Pharmacokinetic-Pharmacodynamic-Pharmacogenetic Study of Actinomycin-D and Vincristine in Children with Cancer |
2008NTLS087
|
2008-13R: In Vivo Measurement of DNA and Protein Adducts in Fanconi Anemia and Non-Fanconi Anemia Patients Undergoing Hematopoietic Stem Cell Transplantation |
2009CG038
|
COG ADVL0813, A Phase I Study of IMC-A12 (Anti-Insulin-Like Growth Factor-I Receptor Monoclonal Antibody) in Combination with CCI-779 (Temsirolimus) in Pediatric Patients with Recurrent or Refractory Solid Tumors |
2009CG113
|
ADVL0912: A Phase 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma |
2009NTCG026
|
COG ALTE05N1 Umbrella Long-Term Follow-Up Protocol |
MT2002-07
|
Allogeneic Hematopoietic Stem Cell Transplant For Patients with High Risk Hemoglobinopathy Using a Non-Myeloablative Preparative Regimen. |
MT2007-10
|
Intrathecal Enzyme Replacement Therapy for Patients with Mucopolysaccharidosis Type I (Hurler Syndrome) |
Clinical Trials Help